Identification and Preclinical Pharmacology of BMS-986104: A Differentiated S1P(1) Receptor Modulator in Clinical Trials

[Image: see text] Clinical validation of S1P receptor modulation therapy was achieved with the approval of fingolimod (Gilenya, 1) as the first oral therapy for relapsing remitting multiple sclerosis. However, 1 causes a dose-dependent reduction in the heart rate (bradycardia), which occurs within h...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:ACS Med Chem Lett
Main Authors: Dhar, T. G. Murali, Xiao, Hai-Yun, Xie, Jenny, Lehman-McKeeman, Lois D., Wu, Dauh-Rurng, Dabros, Marta, Yang, Xiaoxia, Taylor, Tracy L., Zhou, Xia D., Heimrich, Elizabeth M., Thomas, Rochelle, McIntyre, Kim W., Warrack, Bethanne, Shi, Hong, Levesque, Paul C., Zhu, Jia L., Hennan, James, Balimane, Praveen, Yang, Zheng, Marino, Anthony M., Cornelius, Georgia, D’Arienzo, Celia J., Mathur, Arvind, Shen, Ding Ren, Cvijic, Mary Ellen, Salter-Cid, Luisa, Barrish, Joel C., Carter, Percy H., Dyckman, Alaric J.
Formato: Artigo
Idioma:Inglês
Publicado em: American Chemical Society 2016
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4789672/
https://ncbi.nlm.nih.gov/pubmed/26985316
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acsmedchemlett.5b00448
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados